Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBio-4101 and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
NCT06236425Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of tidal-01 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Safety and tolerability up to 2 years. Started Mar 2024; status: completed.
02
Drugs
tidal-01
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06236425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236425.